|Nonuniform cardiac denervation observed by 11C-meta-hydroxyephedrine PET in 6-OHDA-treated monkeys.|
|Jump to Full Text|
|PMID: 22539969 Owner: NLM Status: MEDLINE|
|Parkinson's disease presents nonmotor complications such as autonomic dysfunction that do not respond to traditional anti-parkinsonian therapies. The lack of established preclinical monkey models of Parkinson's disease with cardiac dysfunction hampers development and testing of new treatments to alleviate or prevent this feature. This study aimed to assess the feasibility of developing a model of cardiac dysautonomia in nonhuman primates and preclinical evaluations tools. Five rhesus monkeys received intravenous injections of 6-hydroxydopamine (total dose: 50 mg/kg). The animals were evaluated before and after with a battery of tests, including positron emission tomography with the norepinephrine analog (11)C-meta-hydroxyephedrine. Imaging 1 week after neurotoxin treatment revealed nearly complete loss of specific radioligand uptake. Partial progressive recovery of cardiac uptake found between 1 and 10 weeks remained stable between 10 and 14 weeks. In all five animals, examination of the pattern of uptake (using Logan plot analysis to create distribution volume maps) revealed a persistent region-specific significant loss in the inferior wall of the left ventricle at 10 (P<0.001) and 14 weeks (P<0.01) relative to the anterior wall. Blood levels of dopamine, norepinephrine (P<0.05), epinephrine, and 3,4-dihydroxyphenylacetic acid (P<0.01) were notably decreased after 6-hydroxydopamine at all time points. These results demonstrate that systemic injection of 6-hydroxydopamine in nonhuman primates creates a nonuniform but reproducible pattern of cardiac denervation as well as a persistent loss of circulating catecholamines, supporting the use of this method to further develop a monkey model of cardiac dysautonomia.|
|Valerie Joers; Kailie Seneczko; Nichole C Goecks; Timothy J Kamp; Timothy A Hacker; Kevin G Brunner; Jonathan W Engle; Todd E Barnhart; R Jerome Nickles; James E Holden; Marina E Emborg|
Related Documents :
|24449819 - Does transendocardial injection of mesenchymal stem cells improve myocardial function l...
24463369 - Dominant frequency increase rate predicts transition from paroxysmal to long-term persi...
23788089 - The combined use of transmyocardial laser revascularisation and intramyocardial injecti...
23498679 - Napkin-ring sign on coronary ct angiography for the prediction of acute coronary syndrome.
1118619 - Effects of metrizamide, a new nonionic contrast medium, on cardiac function during coro...
10768439 - Waiting for coronary angiography: is there a clinically ordered queue?
1865349 - The antifibrillatory actions of uk-68,798, a class iii antiarrhythmic agent.
16501619 - The future of cell therapy for acute myocardial infarction.
22026629 - Determining patient prognosis using computed tomography coronary angiography.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2012-04-23|
|Title: PloS one Volume: 7 ISSN: 1932-6203 ISO Abbreviation: PLoS ONE Publication Date: 2012|
|Created Date: 2012-04-27 Completed Date: 2012-09-10 Revised Date: 2013-06-25|
Medline Journal Info:
|Nlm Unique ID: 101285081 Medline TA: PLoS One Country: United States|
|Languages: eng Pagination: e35371 Citation Subset: IM|
|Preclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America.|
|APA/MLA Format Download EndNote Download BibTex|
Blood Pressure / drug effects
Carbon Radioisotopes / chemistry
Dopamine / blood
Ephedrine / analogs & derivatives*, blood, chemistry, diagnostic use
Heart / radionuclide imaging*
Neurons / drug effects
Norepinephrine / blood
Oxidopamine / chemistry, toxicity*
Primary Dysautonomias / diagnosis
Radiopharmaceuticals / chemistry, diagnostic use*
|1UL1RR025011/RR/NCRR NIH HHS; 9U54TR000021/TR/NCATS NIH HHS; P51RR000167/RR/NCRR NIH HHS; UL1 TR000427/TR/NCATS NIH HHS|
|0/Carbon Radioisotopes; 0/Radiopharmaceuticals; 102-32-9/3,4-Dihydroxyphenylacetic Acid; 1199-18-4/Oxidopamine; 299-42-3/Ephedrine; 3002-40-2/3-hydroxyephedrine; 51-41-2/Norepinephrine|
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
Publisher: Public Library of Science, San Francisco, USA
Joers et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Received Day: 3 Month: 11 Year: 2011
Accepted Day: 16 Month: 3 Year: 2012
collection publication date: Year: 2012
Electronic publication date: Day: 23 Month: 4 Year: 2012
Volume: 7 Issue: 4
E-location ID: e35371
PubMed Id: 22539969
Publisher Id: PONE-D-11-22193
|Nonuniform Cardiac Denervation Observed by 11C-meta-Hydroxyephedrine PET in 6-OHDA-Treated Monkeys Alternate Title:Nonuniform Cardiac Denervation in Monkeys|
|Nichole C. Goecks1|
|Timothy J. Kamp3|
|Timothy A. Hacker3|
|Kevin G. Brunner1|
|Jonathan W. Engle4|
|Todd E. Barnhart4|
|R. Jerome Nickles4|
|James E. Holden14|
|Marina E. Emborg124*|
1Preclinical Parkinson's Research Program, Wisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
2Neuroscience Training Program, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
3Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
4Department of Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin, United States of America
|Technical University of Dresden Medical School, Germany
|Correspondence: * E-mail: email@example.com
Contributed by footnote: Conceived and designed the experiments: ME JH TK. Performed the experiments: VJ KS NG TH TK KB JH JE TB RJN ME. Analyzed the data: VJ JH TH TK ME. Contributed reagents/materials/analysis tools: JH ME TK TH. Wrote the paper: VJ JH ME.
Parkinson's disease (PD) is a movement disorder associated with degeneration of the nigrostriatal dopaminergic pathway; however, patients also experience nonmotor symptoms, with up to 80% having some form of autonomic dysfunction , , , . Dysautonomias greatly affect PD patients' quality of life, and often are more disabling than motor deficits .
Cardiac dysautonomia, or abnormal autonomic control of the heart, is characterized in PD by orthostatic hypotension, an increase in corrected QT intervals (QTc), and reductions in heart rate variability and plasma norepinephrine , , , , . Cardiac denervation, which may be a component of dysautonomias or found independently in PD patients, , , ,  is associated with arrhythmias, shortness of breath during exercise, reduced time to peak heart rate, and fatigue , . High co-prevalence suggests cardiac denervation and dysautonomia are intimately related with serious clinical consequences. New screening tools  and treatments are needed.
Cardiac sympathetic loss in PD has been documented using sympathoneuronal imaging agents such as 6-[18F]fluorodopamine , , ,  and 11C-meta-hydroxyephedrine (MHED) ,  with positron emission tomography (PET) and [123I]metaiodobenzylguanidine with single-photon emission computed tomography , , , , . Low uptake in the left ventricle (LV) myocardium is reported in all stages of PD, although specific patterns of loss are not well described. Both diffuse and localized losses to lateral and inferior LV walls are reported , , . Regardless of the pattern, loss is progressive . PD patients exhibited as much as 30% loss of 6-[18F]fluorodopamine uptake in the LV lateral wall over 2 years, with relative preservation in the septal wall . Loss of cardiac sympathetic innervation is confirmed post mortem by nearly complete absence of tyrosine hydroxylase, an enzyme in catecholamine biosynthesis, and by reduced neurofilament protein, a marker for the presence of axons , , .
Development of PD treatments targeting cardiac dysautonomia requires comprehensive animal models mimicking this symptom,  but no well-characterized nonhuman primate model of cardiac dysautonomia is currently available. Systemic administration of 6-hydroxydopamine (6-OHDA) to mice ,  and dogs ,  induces persistent loss of cardiac catecholaminergic innervation, supporting use of 6-OHDA to model cardiac dysautonomias in PD. We therefore aimed to assess the feasibility of developing a monkey model of cardiac dysautonomia by administering 6-OHDA within a system of in vivo evaluation in order to generate preclinical tools toward understanding this condition and testing therapies for PD patients.
The present study was performed in strict accordance with the recommendations in the NIH Guide for the Care and Use of Laboratory Animals (7th edition, 1996) in an AAALAC accredited facility (Wisconsin National Primate Research Center, University of Wisconsin - Madison). Experimental procedures were approved by the Institutional Animal Care and Use Committee of the University at the Wisconsin-Madison (permit number: G00538). All efforts were made to minimize the number of animals used and to ameliorate any distress.
Five adult rhesus monkeys (Macaca mulatta; 5–9 years old; 6–10 kg; two male, three female) were used in this project. The study followed a within-subjects experimental design (Figure 1) in which each animal was used as its own control. This design facilitates matching subjects between groups, reduces the chance of confounding factors, and the number of monkeys used. The animals were individually housed in Group 3 or Group 4 enclosures (cage floor area 4.3 ft.2 or 6.0 ft.2 per animal, height 30 or 32 in.) in accordance with the Animal Welfare Act and its regulations and the 7th edition of the Guide for the Care and Use of Laboratory Animals (1996) with a 12-hour light/dark cycle. Throughout the study, the animals were monitored twice daily by an animal research technician or veterinary technician for evidence of disease or injury (e.g., inappetance, dehydration, diarrhea, depression, lethargy, trauma, etc.) and body weight was documented weekly to ensure animals remained in properly sized cages. Animals were fed commercial nonhuman primate chow (2050 Teklad Global 20% Protein Primate Diet, Harlan Laboratories, Madison, WI) twice daily, supplemented with fruits or vegetables and a variety of forage items and received ad libitum water. Nonhuman primate chow soaked in a protein-enriched drink (Ensure©, Abbott Laboratories, Abbott Park, IL) was offered to stimulate appetite as needed after neurotoxin dosing.
6-OHDA hydrobromide (Sigma-Aldrich, St. Louis, MO) solution was prepared under a certified chemical hood, less than 2 hours before administration. The solution was kept out of light and on ice until immediately before administration, when it was drawn up into a 10-mL syringe covered with foil, and flushed through an amber-colored infusion line. Animals were food-deprived overnight; anesthesia was induced with ketamine HCl (15 mg/kg im) and maintained with 1–3% isoflurane in 100% O2 at 1 L/min. 6-OHDA (total final dose 50 mg/kg) was mixed into a sterile ascorbic acid solution (1 mg/mL 0.9% NaCl) and administered intravenously in a series of 5 mL injections (see Table 1 for dosing scheme) at a rate of 1 mL/min, using a motorized syringe pump (KD Scientific, Holliston, MA). Dosing was based on previous reports administering 6-OHDA to dogs , . Blood pressure, heart rate, respiration rate, blood oxygen, and electrocardiograms (ECG) were monitored throughout the procedure; their normalization (return to baseline values) defined timing of subsequent dosing. Before dosing, blood was taken for complete blood chemistry and hematocrit measurements; additional hematocrit measurements were performed after each dosing.
Heart rate, cardiac auscultation, complete blood count, and blood chemistry were performed at least monthly before and after 6-OHDA. Feces were monitored daily by trained personnel and their characteristics recorded using a descriptive scale. The feces were identified as: no stool, very little stool, firm stool, soft feces (feces not-formed, usually soft or loose), diarrhea (watery or fluid feces), and mucus feces.
A trained observer monitored for PD signs using a previously validated clinical rating scale , . The scale rates tremor (0–3 for each arm), posture (0–2), gait (0–5), bradykinesia (0–5), balance (0–2), gross motor skills (0–4 for each arm), defense reaction (0–2) and freezing (0–2). The total score ranges from 0 (normal condition) to 32 points (extreme severe disability).
A 10-lead ECG (Hewlett-Packard PageWriter, MA) was performed at baseline, during toxin administration, and at 1, 4, 10, and 14 weeks after 6-OHDA. Data were collected at least 15 minutes after starting isoflurane anesthesia. Electrodes were placed on identical positions on the interior right and left arms and legs, the 4th intercostal space immediately right of the sternum (V3), the 5th intercostal space immediately left of the sternum, and directly across from V3 at the anterior axillary line.
An echocardiogram (LOGIQe; GE Healthcare, Waukesha, WI) was performed under 1–3% isoflurane anesthesia in 100% O2 (1 L/min) at baseline and at 10 and 14 weeks after 6-OHDA. Measurements included heart rate, wall thickness, LV chamber diameter, fractional shortening (FS), velocity of blood through mitral and aortic valves, isovolumetric relaxation time, and aortic diameter.
Blood samples for plasma troponin I and catecholamines were obtained at baseline and at 1, 4, 10, and 14 weeks after toxin administration. Blood was collected in a K2 EDTA tube immediately mixed with 10% sodium metabisulfite (0.7%) and centrifuged. For plasma troponin I, samples were analyzed by an enhanced sensitivity immunometric immunoassay as per manufacture instructions (VITROS Immunodiagnostic Products). Plasma norepinephrine, dopamine and epinephrine and their deaminated metabolite dihydroxyphenylacetic acid (DOPAC) were assayed by high-performance liquid chromatography (HPLC) with electrochemical detection (ESA, Chelmsford, MA). Two animals (RH2318 and RH2316) had baseline catecholamines drawn under ketamine and medetomidine, an adrenergic agonist, and were removed from individual catecholamine analysis. A1.0 mL of plasma was analyzed using a coulometric electrochemical detector (Choulochem III; ESA, Chelmsford, MA). Every 1 L of mobile phase used to separate the catecholamines contained 13.8 g of sodium phosphate, 55 mg of 1-octane sulfonic acid, 55 mg of EDTA and 45 mL of acetonitrile at pH of 3.85 and filtered through a 0.22 µm GV filter under vacuum and pumped into the system at a rate of 0.6 mL/min producing a pressure approximately 69–71 bars. The electrodes were set at −250 and 380 mV. Peak heights were measured from the chromatograms and original concentrations of the plasma sample were determined by correcting for the incomplete recovery relative to the internal standards. Coefficients of variation between standards were at acceptable levels for norepinephrine (0.014), epinephrine (0.023), dopamine (0.015) and DOPAC (0.014). For statistical analysis, levels below detectable HPLC sensitivity, were considered as the threshold value (e.g.: epinephrine, 3.0 mg/mL; norepinephrine, 1.5 pg/mL; DOPAC and epinephrine assays were all within detectable ranges).
MHED was prepared by UW-Madison Medical Physics cyclotron facility using published methods . Briefly, [11C]MeI was produced from in-target [11C]CH4 on a 16 MeV GE PETtrace using a Scansys automated chemistry module. Gas phase [11C]MeI labeled 15 mg metaraminol free base (ABX, Germany) in 300 µL 1∶2 DMSO∶DMF. The sealed vial was heated to 110°C for 5 minutes and diluted with 5 mL water for preparative reverse-phase HPLC purification (Econosil 5 µ, 8×300 mm, 3 mL/min 0.1 M Na2HPO4, with EtOH concentration increasing linearly from 0 to 10% over 600 s). The final product was millipore filtered for injection.
Monkeys underwent MHED PET under isoflurane anesthesia (1–3% in 100% O2, 1 L/min) at baseline and at 1, 4, 10, and 14 weeks after 6-OHDA. Animals were positioned supine in a Siemens HR+ PET scanner, using a custom-made foam positioning apparatus. After a 15 minute transmission scan, MHED was injected as an intravenous bolus (≤5.2 mCi) over 30 s. Dynamic PET images were obtained for 1 hour with conventionally increasing frame durations (6×30s, 3×60s, 2×120s, 10×300s).
Whole-blood tracer concentrations were obtained from a volume of interest in the upper part of the LV chamber. MHED uptake was quantified using the equilibrium distribution volume (DV)  of the LV tissue relative to whole blood. A DV value of 1 corresponds to no excess capacity in tissue relative to blood; DV – 1 thus provides a measure of the density of the nerve terminals that give the tissue its excess capacity. DV was evaluated in eight sectors in each of seven short-axis rings evenly spaced along the long axis of the heart. Data are presented as polar maps (apex of the heart at the center, base of the LV at the edge). Intersubject variation was observed at baseline in the apical and basal regions, probably reflecting normal patterns of innervation. Study of one animal (R01097) at the 10-week time point failed for technical reasons; uptake patterns at other time points were similar to those of the other four animals and were included in the visual assessments. Statistical assessments of PET data were performed with only the four remaining animals.
Individual subject global DV was calculated as an average over all eight sectors from polar rings 2 to 6 (total: 40 blocks) at baseline and at 1, 4, 10, and 14 weeks after lesion. These measures were averaged across animals to determine the group global DV at each timepoint. Individual MHED percent retention deficit was calculated for each of the 40 blocks at each time point as [(DVbaseline−1)−(DVtimepoint−1)]/(DVbaseline−1)×100 and averaged over blocks at each time point. These measures also were averaged across animals to obtain group MHED percent retention deficit at the four post-lesion time points.
All statistical analysis was performed using GraphPad Prism (version 5.0b, GraphPad Software). A P<0.05 was accepted as significant. Comparison over time of the different data sets (feces, weights, ECG intervals, echocardiogram data, troponin I and catecholamines levels) were done using repeated measures ANOVA and corrected with Bonferroni multiple comparison tests.
Changes over time of global DV mean and percent retention deficit were assessed by repeated-measures ANOVA and corrected with Tukey's multiple comparisons test. To assess regional variation, individual DV values in the four single sectors in the anterior, septal, inferior, and lateral directions were averaged over the five central rings (total: 5 blocks) to provide a single mean regional value at each time point. Group averaged regional DV values were analyzed with two-way repeated-measures ANOVA among all four regions over time and corrected with Bonferroni multiple comparisons test. Finally, Pearson correlations were performed between MHED uptake and other outcome measures (feces, ECG, blood assays and echocardiogram outputs) and between body weights and frequency of abnormal feces.
Sympathetic responses occurred immediately after each 6-OHDA injection, including increases in systolic and diastolic blood pressure (Figure 2A) and heart rate. Individual animal sensitivity and the tachyphylaxic effect of sympathetic responses to 6-OHDA dosing influenced the time interval between successive doses that ranged from 12 to 100 minutes with the longest period occurring after a cumulative dose of >1.5–3 mg/kg (Table 1; Figure 2B).
In three animals (R01098, R04094, RH2316), ECGs showed arrhythmic activity (e.g., ventricular premature contractions) when the cumulative dose reached >3 mg/kg, which delayed next dosing. Increasing the number of injections (while decreasing the amount of 6-OHDA per injection) and adjusting each dose according to the individual response minimized side effects and reduced time between consecutive doses.
Hematocrit levels were slightly elevated during toxin delivery; peak increases averaged 18.1%. Three animals (R01097, R01098, R04094) vomited during or directly after treatment. All animals produced pink-hued urine after 6-OHDA, probably because of oxidation of 6-OHDA; samples were negative for blood.
Group weekly weights showed body weight loss after 6-OHDA compared to baseline. The weight loss became statistically significant 4 weeks after lesion (12.26%) and remained stable over time (Table 2).
Soft feces or diarrhea were observed after 6-OHDA dosing but did not interfere with general and motor behavior as well as blood hematology and chemistry. The frequency of abnormal feces positively correlated with body weight loss (Pearson's correlation, r2 = 0.516, P<0.0001), in particular diarrhea (r2 = 0.3604, P = 0.0005) and soft feces (r2 = 0.4015, P = 0.0002).
ECGs after 6-OHDA all demonstrated normal sinus rhythm. There were no significant changes in PR, QRS and QTc intervals relative to baseline, despite QTc being considered an indicator of cardiac dysautonomia in Parkinson's disease (Table 3) , .
Echocardiograms revealed variable changes in FS, a measure of systolic performance following 6-OHDA (Table 4). Three animals had a decrease in FS throughout the study with the largest decrease being 43% from baseline. In two of these three animals, there was left ventricular dilation accompanying the systolic dysfunction. Two animals showed no apparent changes in chamber size or FS. There were no notable clinical consequences observed from FS reductions such as signs of heart failure. Evaluation of wall thickness, did not reveal significant changes associated to nonuniform wall innervation (Table 4).
Troponin I levels in four animals were not affected by 6-OHDA. One animal (R04094) had a fivefold increase at 1 week, suggestive of cardiac damage; levels returned to baseline over time.
Plasma catecholamine levels dramatically decreased 1 week after 6-OHDA and remained stable until necropsy (Table 5), with significant reduction in norepinephrine (F2,4 = 6.57, P = 0.012) and DOPAC (F2,4 = 17.20, P = 0.0005) levels. Decreases in dopamine and epinephrine did not reach statistical significance, probably because of individual variability at baseline.
Baseline DV values were uniform, regionally and across animals. DV values fell to ∼1 in all regions in all animals at 1 week after 6-OHDA, and slowly recovered over 3 months with considerable regional variation (Figure 3). Group-averaged global DV values at each time point after 6-OHDA were all significantly lower than at baseline (P<0.001), suggesting reduction of innervation 3 months after 6-OHDA. Similarly, group MHED percent retention deficit values varied significantly over time (F3,3 = 14.38, P<0.001), with reductions noted between 1 and 10 weeks (P<0.01), 1 and 14 weeks (P<0.001), and 4 and 14 weeks after toxin (P<0.05) but not between directly adjacent time points (Figure 4A). The continual increase in MHED uptake suggests slow but global recovery of innervation; however, significant changes were detected between 10 and 14 weeks after toxin challenge, suggesting stabilization of the lesion.
Statistical analysis demonstrated a main effect on each variable region (F3,48 = 5.93, P<0.05) and time (F4,48 = 231.4, P<0.001), in addition to the interaction effect (F12,48 = 2.986, P<0.01). Post hoc analysis between regions over time showed a significant difference between anterior and inferior regions at 10 (P<0.001) and 14 weeks (P<0.01), anterior and septal at 10 weeks (P<0.001), and inferior and lateral at 10 weeks (P<0.01), suggesting that 6-OHDA creates a heterogeneous lesion in the LV myocardium (Figure 4B).
Cardiac MHED uptake was significantly correlated with the natural logarithm of the blood concentrations of norepinephrine (Pearson's correlation; r2 = 0.44, P = 0.0097), dopamine (r2 = 0.596, P = 0.0012), epinephrine (r2 = 0.526, P = 0.0033), and DOPAC (r2 = 0.60, P = 0.0011) at similar time points (Figure 5). Additionally, frequency of abnormal feces significantly corresponded with MHED uptake (r2 = 0.4814, P = 0.0059). No significant correlations were found between MHED and troponin I or FS changes.
To our knowledge, this is the first study to characterize in vivo effects in the heart of systemic 6-OHDA to rhesus monkeys, and the first to track experimental cardiac denervation with MHED PET. The main findings include a nonuniform pattern of MHED uptake in the left myocardium, as well as decrease in circulating catecholamines, suggesting that this model mimics cardiac dysautonomia in PD.
The most common nonhuman primate model of PD involves the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) . Systemic dosing of MPTP produces a severe parkinsonian motor syndrome; however, effects in sympathetic denervation are temporary, as observed with 6-[18F]fluorodopamine PET imaging . The other frequently used PD monkey model depends on direct intracerebral delivery of 6-OHDA, in order to bypass the blood–brain barrier and affect the nigrostriatal pathway without inducing peripheral effects . Our method of intravenous delivery takes advantage of 6-OHDA catecholaminergic toxicity to develop a cardiac dysautonomia model.
The only previous report of systemic administration of 6-OHDA to monkeys was done in a single rhesus to compare the systemic effect of 6-OHDA to MPTP . Yet, the authors did not describe the 6-OHDA method of administration and only provided a 6-[18F]fluorodopamine PET scan image and catecholamine levels 1 week after intoxication. Instead, we based our dosing regime on the reports of 6-OHDA administration to dogs, which described neurotoxin delivery over several hours to avoid clinical complications associated to the dopaminomimetic effects of the neurotoxin , . Intravenous administration of 6-OHDA proved to require intensive monitoring and veterinary care to avoid hypertensive crisis and pulmonary edema. The adjustment of the dosing regimen to the individual animal response decreased the intensity of the symptoms and the time period needed for their normalization and ensured a safe recovery after the procedure.
Reduction in FS after 6-OHDA administration suggests an abnormality in cardiac contractility. These reductions were mild; even the lowest values were within published normal reference ranges , , and were not associated at the time with changes in wall thickness. It should be noted that normal ranges of echocardiogram parameters are not well established for macaque monkeys and the limited data are based on single recordings with different types of anesthesia. Because FS measurements are not well established for monkeys, we evaluated the percent change of FS over time for each individual animal. Three animals in this study had recurring declines in the change of FS following 6-OHDA, suggesting that the loss of noradrenergic cardiac innervation may produce reductions in left ventricular systolic function. The animal with the greatest decrease in FS (R04094) uniquely had increased troponin I levels 1 week after toxin suggesting injury to the myocardium. This was coupled with lack of recovery in the LV MHED uptake from 1 week to 4 weeks, perhaps demonstrating a more severe hypertensive response to 6-OHDA. The other animals did not exhibit elevated cardiac troponin I levels and had no or less of an initial decrease in FS accompanied by greater increases in total MHED uptake.
Noninvasive PET imaging of cardiac sympathetic innervation allowed us to monitor over time the cardiac tissue response to 6-OHDA challenge. We used equilibrium DV relative to whole blood to analyze uptake of MHED, because the uptake index conventionally used  declined rapidly as progressively later time windows were used for estimation. This behavior, and the success of an analysis method that assumes reversibility of the radioligand uptake, are at least partly due to progressive metabolism of MHED into compounds with no specific affinity to noradrenergic terminals. If blood metabolite analysis is not in the protocol, the DV estimates represent the most reproducible and least arbitrary way to use all the measured data to estimate a single number representing the uptake process. The use of DV – 1 to represent the innervation-specific part of the uptake is based on the observation that lesioning reduced the DV values to ∼1 in all regions in all animals.
Systemic administration of 6-OHDA induced loss of catecholaminergic innervation of the heart (greater loss in inferior LV myocardium), which persisted 3 months after toxin challenge. Although nerve terminals in all regions of the LV reacted similarly to 6-OHDA at 1 week, regional rates of recovery varied over time, with an average 51% remaining deficit after 3 months. The anterior region consistently recovered most rapidly and the inferior wall most slowly. Our findings resemble those in PD: MHED PET established loss in sympathetic myocardial innervation  and 6-[18F]fluorodopamine imaging suggested preservation in septal  and anterior  walls of the LV. The nonuniform pattern of MHED uptake may be caused by regional differences in blood perfusion that affected the distribution or metabolism of the neurotoxin. Another possibility is that the subpopulation of ganglionic cells innervating the area has a greater sensitivity to 6-OHDA. It could be argued that the regional recovery was due to re-growth of cardiac muscle tissue, instead of reinnervation. Yet, results from the echocardiogram showed no significant differences in posterior or anterior wall thickness in either diastole or systole. Bai and colleagues  have reported recovery of cardiac sympathetic nerves following subcutaneous delivery of 6-OHDA insult in rats. In addition, sympathetic reinnervation has been described after heart transplantation, suggesting that the system has a certain plasticity that could be exploited for regenerative or neuroprotective treatments , , . Increasing animal numbers would help further define regional differences in LV MHED uptake. Further investigation of the mechanisms of regional loss is needed, as it may facilitate the identification of possible therapeutic targets.
The timeline of our experimental design was based on our previous experience with administration of neurotoxins in the central nervous system of nonhuman primates. For example, an observation period of 3 months after MPTP challenge allows for the dopaminergic nigral cell neurodegeneration to be completed and defines a stable syndrome , , . Lack of significant changes in MHED uptake between 10 and 14 weeks suggests that as predicted, by 3 months the catecholaminergic lesion was stabilized and recovery mechanisms were completed. The characterization of the timeline for recovery and stabilization of the lesion in this model will be helpful when designing a study to test disease-modifying strategies for the heart. Follow-up experiments with endpoints exceeding 14 weeks after toxin administration would further confirm that 6-OHDA produces a stable lesion in the LV.
Dopamine, epinephrine, norepinephrine, and DOPAC circulating levels were significantly decreased after 6-OHDA, which indicates that the neurotoxin affected peripheral catecholaminergic sources such as adrenal medulla, facilitating onset of cardiac dysautonomia. The positive correlation found between catecholamine levels and cardiac MHED uptake further suggests a similar toxic effect of 6-OHDA in different peripheral catecholaminergic cells. The drop in circulating catecholamines did not seem to affect animal health, probably because of adaptive sympathetic presynaptic supersensitivity . Studies in dogs did not find changes in catecholamine levels, suggesting a species difference in the sensitivity to neurotoxin effects .
Cardiac dysautonomia in PD patients is clinically characterized by orthostatic hypotension, an increase in corrected QT intervals (QTc), and reductions in heart rate variability , , , , , , . The presence of these symptoms was not confirmed in this study, because they are detected in an awake state and the cardiac and blood pressure evaluations were performed under anesthesia. Nonuniform cardiac innervation, affects cardiac repolarization and has been associated with arrhythmias , . Future preclinical experiments using telemetric measurements of heart rate, blood pressure, and locomotive activity ,  will allow their identification in awake animals. Injections of vasoactive pharmaceuticals such as phenylephrine or sodium nitroprusside may also help characterize the cardiovascular response.
The monkeys presented abnormal feces and weight loss that became significant 4 weeks after 6-OHDA. The frequency of loose stools and diarrhea correlated with the amount of weight loss. Supplementation of feedings with chow soaked in protein-enriched drink (standard practice in our facility for animals loosing weight) enticed feeding, increased fluid intake and helped prevent further weight loss. The abnormal feces could have been the result from stress (each animal underwent procedures at least monthly), but their presence were also described in 6-OHDA-treated dogs that did not undergo those evaluations, suggesting an effect of 6-OHDA in the gastrointestinal tract . The enteric nervous system consists of dopaminergic neurons (myenteric and submucosal plexus), which are potentially susceptible to the toxic effects of systemic 6-OHDA . In that regard, rats treated with 6-OHDA have decreased TH mRNA levels in the duodenum . Reduced sympathetic innervation of the intestinal tract can lead to bowel dysmotility and, therefore, abnormal feces.
Collectively, the changes in cardiac innervation, catecholamine levels and feces suggest that systemic dosing of 6-OHDA affects multiple vulnerable catecholaminergic peripheral cells, and this property can be applied to model dysautonomias in nonhuman primates. Similar to CNS neurotoxic models, a 6-OHDA-induced dysautonomia model presents limitations like acute onset and the risk for spontaneous recovery . Intravenous administration of 6-OHDA does not induce a PD motor syndrome, therefore a comprehensive PD model would require supplementation with systemic MPTP or direct intracerebral dosing of 6-OHDA to induce dopaminergic nigral cell loss. Postmortem analysis and quantification of catecholaminergic cell and terminal loss in susceptible tissues, as well as evaluation of pathologies typical of PD–related neurodegeneration, such as inflammatory cell response and intracytoplasmic accumulation of alpha synuclein , are warranted to further characterize the effect of 6-OHDA in peripheral catecholaminergic cells.
To conclude, systemic administration of 6-OHDA to rhesus monkeys mimics features of cardiac dysautonomia in PD that can be tracked and mapped in vivo using PET imaging. We hope that these results will facilitate model development to study this symptom and to identify new therapeutic alternatives.
Competing Interests: The authors have declared that no competing interests exist.
Funding: This project was supported in part by the Clinical and Translational Science Award (CTSA) program, previously through the National Center for Research Resources (NCRR) grant 1UL1RR025011, and now by the National Center for Advancing Translational Sciences (NCATS), grant 9U54TR000021. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH). The authors also acknowledge the support of WNPRC NIH base grant P51RR000167, and the faculty startup funds from the University of Wisconsin Graduate School, Medical School, and Medical Physics Department. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
We thank Victoria Carter and Michael Dobbert for excellent technical assistance.
|1.||Jost WH. Year: 2003Autonomic dysfunctions in idiopathic Parkinson's disease.J Neurol250Suppl 1I283012761632|
|2.||Martignoni E,Pacchetti C,Godi L,Micieli G,Nappi G. Year: 1995Autonomic disorders in Parkinson's disease.J Neural TransmSuppl 451119|
|3.||Rajput AH,Rozdilsky B. Year: 1976Dysautonomia in Parkinsonism: a clinicopathological study.J Neurol Neurosurg Psychiatry3910921100188990|
|4.||Martinez-Martin P,Schapira AH,Stocchi F,Sethi K,Odin P,et al. Year: 2007Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients.Mov Disord221623162917546669|
|5.||Chaudhuri KR,Martinez-Martin P,Schapira AH,Stocchi F,Sethi K,et al. Year: 2006International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study.Mov Disord2191692316547944|
|6.||Goldstein DS. Year: 2003Dysautonomia in Parkinson's disease: neurocardiological abnormalities.Lancet Neurol266967614572735|
|7.||Post KK,Singer C,Papapetropoulos S. Year: 2008Cardiac denervation and dysautonomia in Parkinson's disease: a review of screening techniques.Parkinsonism Relat Disord1452453118486523|
|8.||Pursiainen V,Haapaniemi TH,Korpelainen JT,Huikuri HV,Sotaniemi KA,et al. Year: 2002Circadian heart rate variability in Parkinson's disease.J Neurol2491535154012420094|
|9.||Mathias CJ. Year: 1998Cardiovascular autonomic dysfunction in parkinsonian patients.Clin Neurosci515316610785842|
|10.||Oka H,Mochio S,Onouchi K,Morita M,Yoshioka M,et al. Year: 2006Cardiovascular dysautonomia in de novo Parkinson's disease.J Neurol Sci241596516325862|
|11.||Goldstein DS,Holmes C,Li ST,Bruce S,Metman LV,et al. Year: 2000Cardiac sympathetic denervation in Parkinson disease.Ann Intern Med13333834710979878|
|12.||Takatsu H,Nishida H,Matsuo H,Watanabe S,Nagashima K,et al. Year: 2000Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG.J Nucl Med41717710647607|
|13.||Braune S,Reinhardt M,Bathmann J,Krause T,Lehmann M,et al. Year: 1998Impaired cardiac uptake of meta-[123I]iodobenzylguanidine in Parkinson's disease with autonomic failure.Acta Neurol Scand973073149613560|
|14.||Taki J,Nakajima K,Hwang EH,Matsunari I,Komai K,et al. Year: 2000Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. firstname.lastname@example.orgEur J Nucl Med2756657310853813|
|15.||Podrid PJ,Fuchs T,Candinas R. Year: 1990Role of the sympathetic nervous system in the genesis of ventricular arrhythmia.Circulation82I1031131973640|
|16.||Tipre DN,Goldstein DS. Year: 2005Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure.J Nucl Med461775178116269589|
|17.||Goldstein DS,Sharabi Y,Karp BI,Bentho O,Saleem A,et al. Year: 2007Cardiac sympathetic denervation preceding motor signs in Parkinson disease.Clin Auton Res1711812117334896|
|18.||Li ST,Dendi R,Holmes C,Goldstein DS. Year: 2002Progressive loss of cardiac sympathetic innervation in Parkinson's disease.Ann Neurol5222022312210793|
|19.||Berding G,Schrader CH,Peschel T,van den Hoff J,Kolbe H,et al. Year: 2003[N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy.Eur J Nucl Med Mol Imaging3012713112483420|
|20.||Raffel DM,Koeppe RA,Little R,Wang CN,Liu S,et al. Year: 2006PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes.J Nucl Med471769177717079809|
|21.||Orimo S,Ozawa E,Nakade S,Sugimoto T,Mizusawa H. Year: 1999(123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.J Neurol Neurosurg Psychiatry6718919410406987|
|22.||King AE,Mintz J,Royall DR. Year: 2010Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders.Mov Disord261218122421480373|
|23.||Suzuki M,Urashima M,Oka H,Hashimoto M,Taira K. Year: 2007Cardiac sympathetic denervation in bradykinesia-dominant Parkinson's disease.Neuroreport181867187018090328|
|24.||Goldstein DS,Eldadah B,Sharabi Y,Axelrod FB. Year: 2008Cardiac sympathetic hypo-innervation in familial dysautonomia.Clin Auton Res1811511918498023|
|25.||Orimo S,Amino T,Itoh Y,Takahashi A,Kojo T,et al. Year: 2005Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease.Acta Neuropathol10958358815933869|
|26.||Orimo S,Oka T,Miura H,Tsuchiya K,Mori F,et al. Year: 2002Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy.J Neurol Neurosurg Psychiatry7377677712438492|
|27.||Amino T,Orimo S,Itoh Y,Takahashi A,Uchihara T,et al. Year: 2005Profound cardiac sympathetic denervation occurs in Parkinson disease.Brain Pathol15293415779234|
|28.||Emborg ME. Year: 2004Evaluation of animal models of Parkinson's disease for neuroprotective strategies.J Neurosci Methods13912114315488225|
|29.||Porter CC,Totaro JA,Burcin A. Year: 1965The relationship between radioactivity and norepinephrine concentrations in the brains and hearts of mice following administration of labeled methyldopa or 6-hydroxydopamine.J Pharmacol Exp Ther15017225853698|
|30.||Porter CC,Totaro JA,Stone CA. Year: 1963Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice.J Pharmacol Exp Ther14030831613972348|
|31.||Gauthier P,Nadeau R,De Champlain J. Year: 1972Acute and chronic cardiovascular effects of 6-hydroxydopamine in dogs.Circ Res312072174340389|
|32.||Goldstein DS,Grossman E,Tamrat M,Chang PC,Eisenhofer G,et al. Year: 1991Positron emission imaging of cardiac sympathetic innervation and function using 18F-6-fluorodopamine: effects of chemical sympathectomy by 6-hydroxydopamine.J Hypertens94174231649861|
|33.||Emborg ME,Ma SY,Mufson EJ,Levey AI,Taylor MD,et al. Year: 1998Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys.J Comp Neurol4012532659822152|
|34.||Emborg ME,Moirano J,Schafernak KT,Moirano M,Evans M,et al. Year: 2006Basal ganglia lesions after MPTP administration in rhesus monkeys.Neurobiol Dis2328128916766201|
|35.||Rosenspire KC,Haka MS,Van Dort ME,Jewett DM,Gildersleeve DL,et al. Year: 1990Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging.J Nucl Med31132813342384800|
|36.||Logan J,Fowler JS,Volkow ND,Wolf AP,Dewey SL,et al. Year: 1990Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.J Cereb Blood Flow Metab107407472384545|
|37.||Ishizaki F,Harada T,Yoshinaga H,Nakayama T,Yamamura Y,et al. Year: 1996[Prolonged QTc intervals in Parkinson's disease–relation to sudden death and autonomic dysfunction].No To Shinkei484434488672303|
|38.||Deguchi K,Sasaki I,Tsukaguchi M,Kamoda M,Touge T,et al. Year: 2002Abnormalities of rate-corrected QT intervals in Parkinson's disease-a comparison with multiple system atrophy and progressive supranuclear palsy.J Neurol Sci199313712084439|
|39.||Emborg ME. Year: 2007Nonhuman primate models of Parkinson's disease.ILAR J4833935517712221|
|40.||Goldstein DS,Li ST,Holmes C,Bankiewicz K. Year: 2003Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease.J Pharmacol Exp Ther30685586012805479|
|41.||Sleeper MM,Gaughan JM,Gleason CR,Burkett DE. Year: 2008Echocardiographic reference ranges for sedated healthy cynomolgus monkeys (Macaca fascicularis).J Am Assoc Lab Anim Sci47222518210994|
|42.||Gross DR. Year: 2009Normal Cardiac Function Parameters.Gross DRAnimal Models in Cardiovascular Research. 3 edNew YorkSpringer5564|
|43.||Bai J,Ren C,Hao W,Wang R,Cao JM. Year: 2008Chemical sympathetic denervation, suppression of myocardial transient outward potassium current, and ventricular fibrillation in the rat.Can J Physiol Pharmacol8670070918841175|
|44.||Kaye DM,Esler M,Kingwell B,McPherson G,Esmore D,et al. Year: 1993Functional and neurochemical evidence for partial cardiac sympathetic reinnervation after cardiac transplantation in humans.Circulation88111011188353872|
|45.||Bengel FM,Ueberfuhr P,Ziegler SI,Nekolla S,Reichart B,et al. Year: 1999Serial assessment of sympathetic reinnervation after orthotopic heart transplantation. A longitudinal study using PET and C-11 hydroxyephedrine.Circulation991866187110199884|
|46.||Buendia-Fuentes F,Almenar L,Ruiz C,Vercher JL,Sanchez-Lazaro I,et al. Year: 2011Sympathetic reinnervation 1 year after heart transplantation, assessed using iodine-123 metaiodobenzylguanidine imaging.Transplant Proc432247224821839246|
|47.||Emborg ME,Moirano J,Raschke J,Bondarenko V,Zufferey R,et al. Year: 2009Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF.Neurobiol Dis|
|48.||Swanson CR,Joers V,Bondarenko V,Brunner K,Simmons HA,et al. Year: 2011The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys.J Neuroinflammation89121819568|
|49.||Nadeau RA,de Champlain J,Tremblay GM. Year: 1971Supersensitivity of the isolated rat heart after chemical sympathectomy with 6-hydroxydopamine.Can J Physiol Pharmacol4936445572416|
|50.||Slack K,Billing R,Matthews S,Allbutt HN,Einstein R,et al. Year: 2010Subtle cardiovascular dysfunction in the unilateral 6-hydroxydopamine-lesioned rat.Parkinsons Dis201042781020976085|
|51.||Sakata M,Sei H,Toida K,Fujihara H,Urushihara R,et al. Year: 2002Mesolimbic dopaminergic system is involved in diurnal blood pressure regulation.Brain Res92819420111844487|
|52.||Goldstein DS. Year: 2006Orthostatic hypotension as an early finding in Parkinson's disease.Clin Auton Res16465416477495|
|53.||Valappil RA,Black JE,Broderick MJ,Carrillo O,Frenette E,et al. Year: 2010Exploring the electrocardiogram as a potential tool to screen for premotor Parkinson's disease.Mov Disord252296230320976736|
|54.||Cersosimo MG,Benarroch EE. Year: 2008Neural control of the gastrointestinal tract: implications for Parkinson disease.Mov Disord231065107518442139|
|55.||Kawamura M,Schwartz JP,Nomura T,Kopin IJ,Goldstein DS,et al. Year: 1999Differential effects of chemical sympathectomy on expression and activity of tyrosine hydroxylase and levels of catecholamines and DOPA in peripheral tissues of rats.Neurochem Res2425329973233|
|56.||Braak H,Braak E. Year: 2000Pathoanatomy of Parkinson's disease.J Neurol247Suppl 2II31010991663|
Table 1 6-OHDA dosing scheme (mg/kg) for each individual animal.
The rhesus monkeys received 7–9 injections of 6-OHDA solution in one session, accumulating to a total final dose of 50 mg/kg. Dosing and timeline of injections varied based on the individual reaction to 6-OHDA. The normalization (return to baseline measures) of vital signs, ECG, heart rate, and blood pressure was used to define when the next dose could be given.
Table 2 Weekly animal weights (kg) and average group % weight loss before and after 6-OHDA dosing.
|Average group % loss||6.72||9.25||8.40||12.26||12.32||12.78||10.84||13.49||11.92||12.95|
A significant loss of weight was found starting at four weeks post 6-OHDA challenge and persisting throughout the study.
Table 3 Electrocardiogram (ECG) measurements at baseline, 1, 4, 10 and 14 weeks after 6-OHDA for each animal.
|Animal ID||Time||HR (bpm)||PR (ms)||QRS (ms)||QT (ms)||QRS axis||ΔQTc|
QTc was calculated using the Bazett's formula as QT interval/sqrt (RR interval), where the RR interval was calculated 60/HR. ΔQTc was calculated as QTc of each time point minus baseline. No significant differences were found in PR, QRS and QTc intervals obtained in anesthetized animals. HR, heart rate. QTc, corrected QT interval.
Table 4 Echocardiogram measurements at baseline, 10 and 14 weeks after 6-OHDA for each animal.
|Animal ID||Time||AWd (cm)||AWs (cm)||PWd (cm)||PWs (cm)||LVDd (cm)||LVDs (cm)||FS||FS (% change from baseline)|
FS is calculated as [(LVDd – LVDs)/LVDd]×100. Three animals experienced large decreases in FS compared to baseline, but there was no significant change in left ventricle diameter or in anterior and posterior wall thickness. This suggests that the increased luminal dimensions of the left ventricle were not due to the loss of cardiac muscle. AWd, anterior wall thickness in diastole. AWs, anterior wall thickness in systole. PWd, posterior wall thickness in diastole. PWs, posterior wall thickness in systole. LVDd, left ventricle diameter in diastole. LVDs, left ventricle diameter in systole. FS, fractional shortening.
Table 5 Circulating plasma catecholamine levels (pg/mL) at baseline (0) and at 1, 4, 10, and 14 weeks after 6-OHDA in three animals.
|Animal ID||Time||Norepinephrine pg/mL (ln)*||Epinephrine pg/mL (ln)||Dopamine pg/mL (ln)||DOPAC pg/mL (ln)**|
|R01097||0||22.35 (3.11)||10.33 (2.34)||13.25 (2.58)||79.64 (4.38)|
|1||3.61 (1.28)||3.83 (1.34)||1.74 (0.56)||26.48 (3.28)|
|4||4.73 (1.55)||4.08 (1.41)||1.26 (0.23)||13.52 (2.60)|
|10||3.85 (1.35)||nd||1.31 (0.27)||14.46 (2.67)|
|14||nd||nd||2.77 (1.02)||21.29 (3.06)|
|R01098||0||89.92 (4.50)||102.19 (4.63)||86.98 (4.47)||103.77 (4.64)|
|1||4.18 (1.43)||3.20 (1.16)||2.02 (0.70)||14.99 (2.71)|
|4||4.50 (1.50)||6.02 (1.80)||1.36 (0.31)||12.50 (2.53)|
|10||nd||4.11 (1.41)||3.55 (1.27)||12.13 (2.50)|
|14||4.81 (1.57)||5.24 (1.66)||2.82 (1.04)||17.15 (2.84)|
|R04094||0||49.06 (3.89)||20.96 (3.04)||18.49 (2.92)||56.92 (4.04)|
|1||4.25 (1.45)||1.87 (0.63)||3.57 (1.27)||16.82 (2.82)|
|4||3.91 (1.36)||3.35 (1.21)||1.03 (0.03)||16.21 (2.79)|
|10||2.26 (0.81)||3.43 (0.81)||2.49 (0.91)||19.04 (2.95)|
|14||4.39 (1.48)||nd||7.12 (1.96)||21.47 (3.07)|
The values in parentheses are the natural logarithms of the concentration values and used to graph correlations in Figure 5. For statistical analysis, non-detectable levels (nd) levels were considered as the lowest detection level with 1.5 pg/mL for norepinephrine and 3.0 pg/mL for epinephrine. Post hoc analysis with Bonferroni multiple comparisons detected significance at all timepoints compared to baseline for norepinephrine and DOPAC (*P<0.05, ** P<0.01).
Previous Document: ANG-1 TIE-2 and BMPR signalling defects are not seen in the nitrofen model of pulmonary hypertension...
Next Document: Mutational analysis of Cvab, an ABC transporter involved in the secretion of active colicin V.